Gian Lifecare Ltd (GIANLIFE) — shareholding pattern, promoter holding, financials and share price
About Gian Lifecare Ltd (GIANLIFE)
Gian Lifecare Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as GIANLIFE and on the BSE under scrip code 542918. Its ISIN is INE063601012.
Incorporated in 2018, Gian Lifecare Ltd is in the business of independent diagnostic/pathological laboratories [1]
Gian Life Care Limited is primarily engaged in providing diagnostic and healthcare tests, operating major labs in Kanpur and Lucknow.
Established in 1995, Gian Pathology has evolved into a large diagnostic center under the leadership of Arun Kumar Gupta.
Listed peers in Healthcare Service Provider: Dhanvantri Jeevan Rekha Ltd, Clinitech Laboratory Ltd, Looks Health Services Ltd, Dr Lalchandani Labs Ltd, Ashram Online.com Ltd, Boston Commerce Limited.
Valuation & Returns
10 Jul 2026At ₹4.94 a share on 10 Jul 2026, Gian Lifecare Ltd (GIANLIFE) was valued at a price-to-book of 0.27x on a book value of ₹18.6 per share as of Mar 2025. Solomo computes return on equity of -4.99% and return on capital employed of -2.19% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2025 to Dec 2025.
- Industry P/E
- 61.73x
- P/B
- 0.27x
- EPS (TTM)
- ₹-0.93
- Book value / share
- ₹18.6
- ROE
- -4.99%
- ROCE
- -2.19%
- ROA
- -2.67%
- Debt / equity
- 0.3x
- Dividend yield
- 0%
- EBITDA margin
- 1.33%
- 52-week range
- ₹4.67 – ₹17.49
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Gian Lifecare Ltd (GIANLIFE) reported revenue of ₹5.94 crore, net profit of ₹-0.04 crore and earnings per share of ₹-0.04. That compares with revenue of ₹12.78 crore and net profit of ₹4.15 crore in Mar 2024. Figures are consolidated, as filed with the exchanges.
In the quarter ended Dec 2025, revenue was ₹1.12 crore and net profit ₹0.1 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue (₹ cr) | 15.45 | 11.41 | 12.78 | 5.94 |
| Net profit (₹ cr) | 4.37 | 1.06 | 4.15 | -0.04 |
| EPS (₹) | 4.23 | 1.02 | 4.01 | -0.04 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | -2.81% | -25.33% | -49.47% |
| Profit growth | -32.72% | -67.13% | -100.96% |
| Stock price CAGR | -22% | -39% | -65% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 30.17% of Gian Lifecare Ltd (GIANLIFE) (down 1.92 pp QoQ). Promoters have pledged 65.1% of their holding. Market capitalisation was ₹5 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2020.
Largest disclosed public shareholders in Mar 2026: SHIELD MULTISTATE COOPERATIVE CREDIT 12.53%, TEJESH HASMUKH SHAH 4.8%, MANGESH KISANRAO GOTMARE 1.93%, N MOHAN NEELA JUDITH 1.78%, GOPAL DNYANDEO INGLE 1.69%, SUKHDEV SINGH 1.11%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 30.17% | 65.1% | - | - | 69.83% |
| Dec 2025 | 32.09% | 61.2% | - | - | 67.91% |
| Sep 2025 | 32.09% | 61.2% | - | - | 67.91% |
| Jun 2025 | 32.09% | 61.2% | - | - | 67.91% |
| Mar 2025 | 32.09% | 61.2% | - | - | 67.91% |
| Dec 2024 | 32.09% | 61.2% | - | - | 67.91% |
| Sep 2024 | 31.99% | 62.3% | - | - | 68.01% |
| Jun 2024 | 32.82% | - | - | - | 67.18% |